INCATE Portfolio

At smartbax we develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.

Developing novel anti-virulence agents for multi drug resistant TB and difficult to treat infectious diseases

Life saving therapy for Sepsis based on a protein inspired by nature

Olgram is a preclinical stage biotechnology company, creating new drugs to fight bacterial persisters (bacteria in a dormant state responsible for infectious relapses), by using an original approach on new chemical entities discovered in the sea

Fagoterapia LAB is the biotech producing and commercializing tailor-made drugs based on good viruses (phage) to cure antibiotic resistant infections. To develop its products FL will leverage on a technology platform based on a proprietary AI-algorithm and on a phage biobank

OSPT is developing a new material integrating bacteriophage viruses, to produce medical implants reducing surgical site infections and the need for antibiotics

Developing novel Darobactin analogues

The Helmholtz Centre for infection Research together with the Lead Discovery Center develop small molecule-based inhibitors of alpha-hemolysin to treat lung infections caused by Staphylococcus aureus

MyxoBiomedical develops a resistance-breaking macrolide antibiotic based on the myxobacterial natural product scaffold chlorotonil for the treatment of infections caused by MRSA/VRE

Kinzbio is discovering phages that have been overlooked by standard discovery pipelines and have unique and previously unknown biological properties, leveraging their use for infection prevention

At CC Bio, we harness the power of synthetic biology to engineer and edit the microbiome with precision antimicrobials. Our goal is to eliminate microbiome-based disease in a potent, specific and prophylactic fashion, harmonising the relationship between eukaryotic and microbial cells

An antibacterial peptide that inhibits replication and mutagenesis

Utilizing UV light, Puray provides the world’s first permanently disinfected medical tubing, offering superior infection prevention for patients

Xiretsa is developing novel membrane-remodeling small-molecule antibiotics that evade resistance to address the greatest Gram-negative, Gram-positive, and Mycobacterial threats

With a new mechanism of action, a new class of compound and a new target, Disperazol is a robust, narrow-spectrum drug candidate with significant efficacy in inhibiting and dismantling Pseudomonas aeruginosa biofilms

The University Hospital Bonn together with Helmholtz Centre for Infection research develops the natural compound Corallopyronin A for difficult-to-treat Gram-positive infections, with funding from DZIF

MetalloBio is a deep-tech antimicrobials development company which is advancing 2 completely new classes of compounds, based on a proprietary inorganic chemistry platform with broad-spectrum against all WHO pathogens of concern; showing little to no emergence of genetic resistance, effective against bacteria with various resistance mechanisms, and showing no antagonism with existing antibiotics tested to date

Building an integrated company for Phage Therapy

Paerublock develops non-traditional small molecules targeting elastase (LasB) from Pseudomonas aeruginosa as novel antibiotic therapeutics

ARIVA Med focuses on developing innovative anti-infectives to combat antimicrobial resistance. Its lead program, the Epimutilins, features novel compounds with strong antibacterial activity against priority pathogens, unaffected by resistance to other antibiotic classes, addressing critical global health threats identified by the WHO and CDC.

SimCells® are genome-free bacteria produced by switchable enzymatic shearing, which inactivates bacterial cells while preserving immunogenic cell surface features, offering a new approach to creating safe and effective whole-cell vaccines against bacterial pathogens

The goal the project is to further develop IND enabling data for a series of high-performing bacteriophages to be formulated into a single, fixed product for the treatment of MDR pathogens in recurrent urinary tract infections (rUTI) and someday be applied in clinical settings.

Small synthetic, narrow-spectrum resistance-breaking antibiotics against Acinetobacter baumannii.

Leveraging its proprietary platform technology on marine natural products to develop highly effective antibiotics against hard-to-treat and intractable bacterial diseases.

Microplate Dx is an award-winning spinout company specializing in developing rapid antibiotic susceptibility testing diagnostics.

Theralia is developing the first oligonucleotide-based antibiotics, Therapeutic Oligonucleotides Activated by Nucleases (TOUCANs), for the targeted delivery of antibacterial molecules into infection area that enables a safer and more effective treatment for bacterial infections.

Omnicin Therapeutics is developing metal-containing inhalation therapies to resensitize multi-resistant bacteria to antibiotics”.

Providing next generation immunotherapy for life-threatening, invasive fungal infections.

Developing patient-derived human monoclonal antibodies as new, safe and more effective anti-infective drugs.

First-in-class peptide drug candidates as a novel intervention against Streptococcus pneumoniae.

Pioneering a next-generation live biotherapeutic product (LBP) engineered to precisely target and eradicate multi-drug-resistant and pathogenic bacteria from the gut.

Transforming bacteriophage therapy through engineering to deliver the next generation of precision antimicrobials.

Invitris developed the worldwide first platform technology to synthesize arbitrary phages within a single system, thus enabling full scalability of therapeutic phage isolation, modification, production, and application.

Tackling resistant infections with virulence inhibition.

Rostra Therapeutics is committed to bringing novel medicines to patients and clinicians delivering the power to restore health and save lives globally

Unison Medicines develops small molecule inhibitors of RecA to be used in combination with other front-line antibiotic agents.

LimmaTech Biologics AG is a clinical stage biopharmaceutical company focused on the development and manufacture of next generation vaccines for the prevention of life-threatening diseases.

an ultra-fast, low cost, high-throughput Antimicrobial Susceptibility Test suitable for all bacterial infections

Utilizing UV light, Puray provides the world’s first permanently disinfected medical tubing, offering superior infection prevention for patients

SoundCell has developed a rapid phenotypic Antimicrobial susceptibility testing device that delivers AST in one hour.